Novo och Astra ligger bra till i internationell kraftmätning

Patentutgångar kommer under de närmaste åren att drabba flera stora läkemedelsbolag, men Astrazeneca och Novo Nordisk hör till de som skymtar ljusglimtar enligt en analys.

Ny vd för Roche Sverige

Läkemedelsjättens nya Sverige-chef är internrekryterad från Italien.

Så här blir det nya 10-talet!

Vi är i början av ett helt nytt decennium, 10-talet. Framtiden är som alltid oviss och ingen vet vad det nya decenniet verkligen innebär. Hur kommer 10-talet att påverka bolagen i vår bransch? På flera sätt tror jag att 10-talet kommer att ses som en vändpunkt.

Här är hela listan med de svenska ERC-miljonerna

Totalt har 236 forskare fått pengar från det europeiska forskningsrådet ERC. Tolv av dem kommer att arbeta med sina projekt i Sverige.

Bioteknikföretagen framstår som vinnare

USA:s kongress båda kammare lyckades innan jul med knapp marginal rösta igenom var sin version på sjukvårdsreform. Nu återstår den svåra balansakten att få ihop de båda förslagen till ett. Mycket återstår men bioteknikföretagen har all anledning att vara optimistiska.

EU har siktet på Lundbeck

EU-kommissionen kommer att granska om den danska läkemedelsjätten har brutit mot EUs regler för konkurrens. Granskningen gäller hur Lundbeck har agerat kring generika av bolagets preparat citalopram.

Per Norstedt, Regional Manager, AH Diagnostics

Why are you going to Scanlab+Biotech Forum?

Cate Poulsen, Qiagen

Why are you going to Scanlab and Biotech Forum?

Urvattnat sjukvårdsförslag i USA

Nervceller har skydd mot HIV

Neuroner har ett naturligt skydd mot viruset och upptäckten öppnar för nya behandlingsmöjligheter.

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.

Biotech goes white and bright

White biotech could become Denmark's next blossoming business area.

Woman deficit in Swedish research

The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.

Swedish multi competent machine soon launched

The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.

LEO Pharma - International Clinical Trial Manager

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

Biogaia's advance goes on

In December Biogaia reached China and North America. Now, the Swedish probiotic company has entered the Mexican market.

Recipharm launches into biologics manufacturing

Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.

Control of blood vessels can treat obesity

Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet.

Mathematician new dean at DTU

On January 1st the Technical University of Denmark, DTU, got a new dean, recruited from the department of Mathematics.

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.

Ambassador program makes MVA big in Japan

The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a significant difference for their sister clusters.